NICE, France, April 4, 2016 -- In new research published in the latest issue of the Journal of Index Investing, entitled "Smart Beta is not Monkey Business," ERI Scientific Beta has rejected the claims of "monkey portfolio" proponents, who argue not only that all smart beta strategies generate positive value and small-cap exposure, which fully explains their outperformance, but also that similar results are obtained by any random portfolio strategy, including the inverse of such strategies. The "monkey" label comes from the idea that a monkey would be able to generate similar performance through a random selection of stocks.
The ERI Scientific Beta paper analyses these claims using test portfolios which follow commonly-employed methodologies for explicit factor-tilted indices. The results directly invalidate all of the above claims. In particular, the results show that many smart beta strategies display exposure to factors other than value or small cap, as well as pronounced differences in factor exposures across different strategies.
In addition, and perhaps reassuringly, the inverse of these strategies generates inferior performance. That the findings directly contradict the monkey portfolio claims can be explained by the set of test portfolios. While the monkey portfolio arguments may hold for the particular smart beta specifications tested by its proponents, they do not hold in general. Specifically, the research conducted shows that only the indices termed "fundamental" behave like monkey portfolios, on the one hand because their method of construction is based on accounting criteria that are not associated with any statistically significant risk premium over the long term, and on the other because their high level of concentration results in a large proportion of specific risk that leads to performance that lacks robustness and is therefore random.
An important implication of the results is that one should take care to avoid over-generalising from testing particular specifications of smart beta. For the explicit factor-tilted strategies tested in this new research, the results imply that a careful assessment of investment philosophy and index design is indeed relevant as such strategies do not behave like "monkey" portfolios.
As part of its policy of transferring know-how to the industry, EDHEC-Risk Institute has set up ERI Scientific Beta. ERI Scientific Beta is an original initiative which aims to favour the adoption of the latest advances in smart beta design and implementation by the whole investment industry. Its academic origin provides the foundation for its strategy: offer, in the best economic conditions possible, the smart beta solutions that are most proven scientifically with full transparency of both the methods and the associated risks.
ERI Scientific Beta, 1 George Street, #07-02, Singapore 049145. For further information, please contact: Séverine Cibelly, Tel.: +33 493 187 863, E-mail: [email protected], Web: www.scientificbeta.com.
Press_release_Smart_Beta_Monkey_Business http://hugin.info/157174/R/2000399/737961.pdf
HUG#2000399


Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Italy Fines Apple €98.6 Million Over App Store Dominance
FDA Approves Mitapivat for Anemia in Thalassemia Patients
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 



